ALK重排转移性肺癌患者阿来替尼治疗期间妊娠首例报告
首例ALK重排转移性肺腺癌患者在阿来替尼治疗期间妊娠,多学科团队管理下继续用药至分娩,孕35周5天产下健康女婴,婴儿随访20个月无发育异常,母亲诊断后32个月仍部分缓解。
要点
- 阿来替尼治疗期间妊娠可经多学科团队管理继续用药。
- 分娩时母体血浆阿来替尼浓度约为胎儿的14倍(259 vs 18 ng/mL)。
- 婴儿随访20个月未见发育异常,母亲32个月时部分缓解。
核心结论
- 首例报告显示ALK重排转移性肺腺癌患者在阿来替尼治疗期间妊娠,继续用药并多学科管理下母婴结局良好。
研究设计与样本
- 单例病例报告,患者为ALK重排转移性肺腺癌,妊娠期间继续阿来替尼治疗,由妇科、新生儿科、肿瘤科、心理科和药理学科多学科团队管理。
主要发现
- 患者孕35周5天分娩健康女婴,妊娠期间胎儿参数正常。
- 分娩时母体血浆阿来替尼浓度为259 ng/mL,胎儿为18 ng/mL,母体约为胎儿的14倍。
- 胎盘阿来替尼平均浓度为562 ng/g。
- 婴儿随访至20个月未见发育异常。
- 母亲诊断后32个月病情良好,处于部分缓解。
临床怎么用
- 对于ALK重排转移性肺癌患者在阿来替尼治疗期间妊娠,可考虑多学科团队协作并根据患者意愿决定是否继续用药。
局限性
- 为单例病例报告,结论不能推广至所有患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This is the first case report of a patient with ALK-rearranged metastatic lung adenocarcinoma who became pregnant during treatment with alectinib. A multidisciplinary team of gynecologists, neonatologists, oncologists, psychologists, and pharmacologists was set up to handle the case. According to patient's preference, the study drug was continued throughout pregnancy and the woman delivered a healthy baby girl at 35 weeks and 5 days of gestation. Fetal parameters remained normal during pregnancy. At birth, alectinib levels were 14 times higher in maternal plasma than in the fetus (259 versus 18 ng/mL). The average concentration of alectinib in the placenta was 562 ng/g. The baby was followed during her first 20 months, and no developmental anomalies were observed. After 32 months from diagnosis, the mother is well and in partial remission.
引用
- Scarfone G, Fumagalli M, Imbimbo M, et al. First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. J Thorac Oncol. 2021. PMID: 33795207. doi:10.1016/j.jtho.2021.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。